Oruka Therapeutics (ORKA) to Release Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Oruka Therapeutics Trading Down 2.0 %

NASDAQ:ORKA opened at $10.64 on Wednesday. Oruka Therapeutics has a twelve month low of $10.52 and a twelve month high of $53.88. The company has a market capitalization of $372.39 million, a PE ratio of -1.70 and a beta of 0.77. The firm has a fifty day moving average of $15.17.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ORKA shares. Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Wedbush restated an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $39.86.

Check Out Our Latest Stock Analysis on Oruka Therapeutics

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

See Also

Earnings History for Oruka Therapeutics (NASDAQ:ORKA)

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.